Atrix Laboratories, Inc.

Tolmar Therapeutics, Inc.

Richards Medical Company

Vipont Pharmaceutical, Inc.

Southern Research Institute

Sharpoint L.p.

Qlt Usa, Inc.

Other

US Government As Represented by the Secretary of the Army

Pfizer Corporation

Eli Lilly and Company

Repromed, Inc.

Dunn Research & Consulting, LLC

Texas Health Science Center

Richard L Dunn

Arthur J Tipton

Donald R Cowsar

James Perry English

Bhagya L Chandrashekar

David P Vanderbilt

Deryl D Swanbom

George L Southard

Jack A Rogers

Kenneth C Godowski

Gerald L Yewey

Richard L Norton

Danny H Lewis

Ronald J Harkrader

John Steven Garrett

Kenneth S Peterson

Alan M Polson

Bryan K Lowe

Charles P Cox

Harish Ravivarapu

Mingxing Zhou

Thomas W Sander

Shawn M Fujita

Jeffrey L Southard

David D Vanderbilt

Gerbrand Brouwer

Michael L Radomsky

Nancy L Krinick

Robert A Casper

Scott A Jeffers

James A Davidson

Neil B Beals

Richard W Treharne

Leonard E Laufe

Yancy L Gill

Eileen M Jarr

Michelle Botz

John E Urheim

Mei Li

Thomas J Laughlin

Sam R Marchand

F Barry Bays

Richard W Korsmeyer

Cody L Yarborough

Philip J Burck

Ronald E Zimmerman

Gerald W McNeely

Vishwas Madhav Paralkar

Richard N Terry

Francis Dumont

Carlton A Eddy

John W Gibson

Kathleen A McEnery

A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.

Sustained release polymer

The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.

Polymeric delivery formulations of leuprolide with improved efficacy

The present invention relates generally to medical devices for mixing, preparing and administering therapeutic compositions, and more particularly to a system comprising two syringes and a locking ring wherein two compositions are mixed between the two syringes immediately prior to administration.

Coupling syringe system and methods for obtaining a mixed composition

Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided.

Low viscosity liquid polymeric delivery system

The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.

Controlled release polymeric compositions of bone growth promoting compounds

The invention is provides a composition for sustained delivery of a biologically active agent comprising a biologically active mixture and a controlled release formulation. The composition protects the biologically active agent from being destroyed by the controlled release composition. The biologically active mixture includes the biologically active agent and a pharmaceutically acceptable protective carrier. The controlled release formulation includes a pharmaceutically acceptable, biodegradable, matrix forming material that is substantially insoluble in aqueous or body fluids and a pharmaceutically acceptable organic solvent. The biologically active mixture is combined with the controlled release formulation to form an emulsion, the delivery composition, which is then administered to a patient. The protective carrier can be an aqueous substance, a non-aqueous substance or a combination of both. The matrix forming material can be a polymeric material, a non-polymeric material or a combination of both. The organic solvent can have a solubility ranging from a high water solubility to a low water solubility.

Emulsions for in-situ delivery systems

The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.

Controlled release liquid delivery compositions with low initial drug burst

Growing community of inventors

Fort Collins, CO, United States of America

Richard L Dunn